Ceyda Sönmez

Ms. Ceyda Sönmez

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2026 in Life
Verified
Journal Article
Open access
PDF file
CSCeyda Sönmez
Ceyda Sönmez
ABAleyna Baltacioglu
Aleyna Baltacioglu
JCJulide Coskun
Julide Coskun
GDGulen Melike Demirbolat
Gulen Melike Demirbolat
OGOzgul Gok
Ozgul Gok
AOAYSEL OZPINAR
AYSEL OZPINAR
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by invasive growth, intrinsic drug resistance, and the presence of the blood–brain barrier. All of these features make treatment extremely challenging and underscore the need for developing effective combination strategies and advanced drug delivery systems. This study aimed to develop a bovine serum albumin (BSA) nanoparticle (NP)-based delivery system to overcome the poor bioavailability and pharmacokinetic limitations of two potent anti-tumor agents, all-trans retinoic acid (ATRA) and curcumin (CURC), and to evaluate their antitumor activity in U87-MG GBM cells. Drug-free and ATRA/CURC-loaded BSA-NPs were synthesized using an optimized desolvation method and characterized in terms of particle size, polydispersity index, morphology, drug encapsulation efficiency, and release behavior. The cytotoxic, anti-migratory, and pro-apoptotic effects of the NPs on U87-MG GBM cells were assessed using real-time proliferation and migration assays and Annexin V/PI staining followed by flow cytometry. Collectively, the findings indicated that the co-delivery of ATRA and CURC using BSA-NPs showed enhanced antiproliferative, antimigratory, and pro-apoptotic effects. With its controlled release profile, high loading capacity, and favorable nanoscale dimensions, the ATRA-CURC-BSA–NP system represents a promising nanoplatform for GBM therapy that warrants further in vivo investigation. To the best of our knowledge, this is the first study demonstrating the inhibition of glioblastoma cell growth through the co-delivery of all-trans retinoic acid and curcumin using a bovine serum albumin-based nanoparticle system.

1 January 2026 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
AOAYSEL OZPINAR
AYSEL OZPINAR
CSCeyda Sönmez
Ceyda Sönmez
ABAleyna Baltacioglu
Aleyna Baltacioglu
OAOsman Acar
Osman Acar
MKMeltem Kilercik
Meltem Kilercik
FSFlorian J. Schweigert
Florian J. Schweigert
Oxidative stress and inflammation play central roles in the immunopathogenesis of COVID‐19. In this study, we investigated whether circulating carotenoids, retinol, and vitamin E metabolites can distinguish COVID‐19 patients from healthy controls and discriminate disease severity. We analyzed 44 hospitalized COVID‐19 patients (23 with moderate disease and 21 with severe disease) and 39 healthy controls recruited from the same hospitals. Plasma concentrations of individual carotenoids, retinol, total vitamin A, vitamin E (γ‐tocopherol, α‐tocopherol), retinol‐binding protein 4 (RBP4), transthyretin (TTR), complete blood count parameters, and clinical chemistry and inflammatory markers were determined and statistically analyzed. Compared with healthy controls, COVID‐19 patients had significantly lower concentrations of vitamin E, retinol, total vitamin A, lutein, total carotenoids, and TTR and higher levels of inflammatory markers. In multivariate logistic regression, the RBP4/total vitamin A ratio, γ‐tocopherol, and ferritin emerged as independent factors differentiating COVID‐19 patients from healthy controls. Within the patient group, antioxidant micronutrient levels did not differ significantly between moderate and severe COVID‐19, whereas inflammatory markers, such as C‐reactive protein, ferritin, and the neutrophil‐to‐lymphocyte ratio, increased with severity. These data indicate that although carotenoids, vitamin A, and vitamin E are markedly depleted during COVID‐19, they do not stratify disease severity, whereas the RBP4/total vitamin A ratio, γ‐tocopherol, and ferritin may serve as useful biomarkers for distinguishing COVID‐19 from health.

Verified
Journal Article
Open access
PDF file
ABAleyna Baltacioglu
Aleyna Baltacioglu
OAOsman Acar
Osman Acar
CSCeyda Sönmez
Ceyda Sönmez
YSYeşim Sağlıcan
Yeşim Sağlıcan
ÖAÖmer Burak Argun
Ömer Burak Argun
AOAYSEL OZPINAR
AYSEL OZPINAR
Non-muscle-invasive bladder cancer (NMIBC) is characterized by high recurrence rates and necessitates lifelong cystoscopic surveillance, underscoring the need for minimally invasive biomarkers to improve early detection and risk stratification. Therefore, this study aimed to investigate the role of trimethylamine-N-oxide (TMAO) and its precursors as diagnostic biomarkers for NMIBC. A total of 50 male patients with NMIBC (25 pTa and 25 pT1) were included in this study. Additionally, 52 age-matched healthy individuals were included as controls. Serum TMAO and its dietary precursors were quantified using liquid chromatography–tandem mass spectrometry. Group differences were analyzed using nonparametric tests, associations were assessed using Spearman’s correlation, and diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Multivariate logistic regression was performed to identify independent predictors, and a composite risk score was generated. Serum TMAO, carnitine, and choline levels were significantly higher in patients with NMIBC than in controls (p ≤ 0.0001), whereas betaine showed a nonsignificant trend toward higher levels (p ≥ 0.05). The pathological stage (pTa vs. pT1) showed the strongest correlation with TMAO levels. The ROC analysis revealed that TMAO had the highest individual diagnostic accuracy (area under the curve [AUC] = 0.875, 95% confidence interval [CI] 0.812–0.939), whereas carnitine and choline provided complementary diagnostic performance. In multivariate models, TMAO, carnitine, and choline remained independent predictors of NMIBC (p ≤ 0.0001). A composite risk score integrating all four metabolites demonstrated excellent discriminatory capacity (AUC = 0.958, 95% CI 0.926–0.991). The TMAO metabolic axis can be used as a minimally invasive biomarker panel for NMIBC. Further large, prospective, multicenter studies integrating metabolomic and microbiome profiling are needed to validate the findings.

Verified
Journal Article
Open access
PDF file
CSCeyda Sönmez
Ceyda Sönmez
MAMeric A Altinoz
Meric A Altinoz
ABAleyna Baltacioglu
Aleyna Baltacioglu
BEBüşra Ergün
Büşra Ergün
AOAYSEL OZPINAR
AYSEL OZPINAR
Persistently poor glioblastoma (GBM) survival necessitates better elucidation of tumor drug responses. After observing that low curcumin and all-trans retinoic acid (ATRA) doses stimulated cell proliferation and counteracted each other’s high-dose antiproliferative effects in U87 GBM cells, drug influences on cell growth, migration, and death and the antiproliferative interaction proteome were further studied. Cell proliferation and migration were assessed by xCELLigence Real-Time Cell Analysis (RTCA). Cell death was defined using flow cytometry. Drug interactions were determined with CompuSyn software (version 1.0). Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS), High-Performance Liquid Chromatography (HPLC), and SequestHT software (version 1.4) were utilized for peptide generation and identification. ATRA at high doses inhibited cell growth and migration more efficiently. Curcumin was more proliferative and antagonistic against anti-growth effects at low doses. Migration inhibition and apoptosis occurred synergistically at the highest drug doses. ATRA influenced the proteome more remarkably, reducing Transforming Growth Factor Beta Induced (TGFBI), Phosphoglycerate Dehydrogenase (PHGDH), tenascin, and Sequestosome 1 (SQSTM1). These effects were alleviated by curcumin, except for SQSTM1. Uveal Autoantigen With Coiled-Coil Domains And Ankyrin Repeats (UACA) and Sad1 And UNC84 Domain Containing 2 (SUN2) were increased by ATRA and curcumin, and to a lesser extent by the combination. Hexokinase 2 (HXK2) was increased by curcumin and the combination. Heme Oxygenase 1 (HMOX1) was depleted by the combination, but not by the single agents. SQSTM1 and HMOX1 reductions may mediate anticancer synergism, while the remaining changes may indicate ongoing hormetic pathways not reflected in cell counts.